Zacks upgrades K2M stock to 'buy' rating — 5 points

Spinal Tech

Zacks Investment Research upgraded K2M's rating from "hold" to "buy" on Oct. 5, according to BBNS.

Here are five points:


1. Zacks has a $20 price objective on K2M's stock.


2. The firm also estimates a potential upside of 11.11 percent.


3. With a 50-day moving average of $16.82, K2M has a 200-day moving average of $15.37.


4. The company's market capitalization is $758.61 million.


5. K2M's 52-week low is $10.10 and its 52-week high is $21.67.


Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers